AU2002218026A1 - Cardiovascular disease diagnostic and therapeutic targets - Google Patents
Cardiovascular disease diagnostic and therapeutic targetsInfo
- Publication number
- AU2002218026A1 AU2002218026A1 AU2002218026A AU1802602A AU2002218026A1 AU 2002218026 A1 AU2002218026 A1 AU 2002218026A1 AU 2002218026 A AU2002218026 A AU 2002218026A AU 1802602 A AU1802602 A AU 1802602A AU 2002218026 A1 AU2002218026 A1 AU 2002218026A1
- Authority
- AU
- Australia
- Prior art keywords
- cardiovascular disease
- therapeutic targets
- disease diagnostic
- diagnostic
- targets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24745700P | 2000-11-09 | 2000-11-09 | |
US60/247,457 | 2000-11-09 | ||
PCT/US2001/046816 WO2002038794A2 (en) | 2000-11-09 | 2001-11-08 | Cardiovascular disease diagnostic and therapeutic targets |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002218026A1 true AU2002218026A1 (en) | 2002-05-21 |
Family
ID=22935011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002218026A Abandoned AU2002218026A1 (en) | 2000-11-09 | 2001-11-08 | Cardiovascular disease diagnostic and therapeutic targets |
Country Status (3)
Country | Link |
---|---|
US (6) | US7432060B2 (en) |
AU (1) | AU2002218026A1 (en) |
WO (1) | WO2002038794A2 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
US7670769B2 (en) * | 2002-05-09 | 2010-03-02 | The Brigham And Women's Hospital, Inc. | IL1RL-1 as a cardiovascular disease marker and therapeutic target |
JP2006517092A (en) * | 2002-11-27 | 2006-07-20 | アルテシアン セラピューティック,インコーポレイティド | Heart failure gene determination and therapeutic drug screening |
EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7729761B2 (en) * | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US20070036770A1 (en) * | 2005-08-12 | 2007-02-15 | Wagner Darrell O | Biologic device for regulation of gene expression and method therefor |
US7774057B2 (en) | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
JP5383480B2 (en) | 2006-04-24 | 2014-01-08 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | Predict fatality and detect serious disease |
ATE517341T1 (en) * | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
EP3059594A1 (en) | 2006-05-01 | 2016-08-24 | Critical Care Diagnostics, Inc. | Prognosis of cardiovascular disease |
PL2019965T3 (en) | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics Inc | Differential diagnosis between pulmonary and cardiovascular disease |
US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
WO2008075349A1 (en) * | 2006-12-18 | 2008-06-26 | Immune System Key Ltd. | Therapeutic methods using a thymus peptide |
PT2660599E (en) | 2008-04-18 | 2014-11-28 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
WO2011127412A2 (en) | 2010-04-09 | 2011-10-13 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
JP6215713B2 (en) | 2011-03-17 | 2017-10-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | How to predict the risk of adverse clinical outcomes |
PL2734222T3 (en) | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
ES2709697T3 (en) | 2012-05-18 | 2019-04-17 | Critical Care Diagnostics Inc | Procedures for treatment or prediction of the risk of a ventricular tachyarrhythmia event |
CN107478841A (en) | 2012-08-16 | 2017-12-15 | 重症监护诊断股份有限公司 | The method of risk of hypertension is suffered from prediction |
SG11201501271TA (en) | 2012-08-21 | 2015-03-30 | Critical Care Diagnostics Inc | Multimarker risk stratification |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
US20160051514A1 (en) * | 2013-05-03 | 2016-02-25 | The Brigham And Women's Hospital, Inc. | Methods for treatment of cardiomyopathy |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
TWI765420B (en) * | 2020-11-20 | 2022-05-21 | 英業達股份有限公司 | Assembly of heart failure prediction |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
US5206140A (en) | 1988-06-24 | 1993-04-27 | Research Corporation Technologies, Inc. | Assay for soluble crosslinked fibrin polymers |
US5217899A (en) * | 1990-08-24 | 1993-06-08 | The General Hospital Corporation | Cell stretching apparatus |
JP2665850B2 (en) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | Monoclonal antibody recognizing the C-terminus of hBNP |
GB9211686D0 (en) * | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
JP2732005B2 (en) | 1992-12-14 | 1998-03-25 | 眞一 富永 | DNA encoding human ST2, expression product of the DNA, and method for producing expression product by expressing the DNA |
JPH0731479A (en) | 1993-02-23 | 1995-02-03 | Shinichi Tominaga | Dna of coding murine st2l, expression product of the same dna and production of expression product by expressing the same dna |
US6066322A (en) * | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
WO1998007754A1 (en) | 1996-08-23 | 1998-02-26 | Human Genome Sciences, Inc. | T1 receptor-like ligand ii |
WO1998038311A1 (en) * | 1997-02-28 | 1998-09-03 | Human Genome Sciences, Inc. | T1/st2-receptor ligand iii |
ES2239801T3 (en) | 1997-04-02 | 2005-10-01 | The Brigham And Women's Hospital, Inc. | USE OF AN AGENT TO DECREASE THE RISK OF CARDIOVASCULAR DISEASE. |
JP5264026B2 (en) | 1997-06-10 | 2013-08-14 | エルパス・インコーポレイテッド | Methods for early detection of heart disease |
GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
GB9827348D0 (en) | 1998-12-12 | 1999-02-03 | Univ Leicester | Natriuretic peptide |
EP1140137A2 (en) * | 1998-12-18 | 2001-10-10 | Scios Inc. | Method for detection and use of differentially expressed genes in disease states |
AU5309600A (en) | 1999-06-02 | 2000-12-18 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
FR2795823B1 (en) | 1999-07-01 | 2001-11-23 | Inst Nat Sante Rech Med | METHODS AND KITS FOR DIAGNOSING OR MONITORING SYNOVIAL OR OSTEOARTICULAR PATHOLOGY INCLUDING THE USE OF A SPECIFIC MARKER FOR THE DEGRADATION OF SYNOVIAL TISSUE |
US6323334B1 (en) * | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
FR2807170B1 (en) | 2000-03-30 | 2002-06-28 | Sipal | ELASTIC HINGE WITH REDUCED FRICTION |
BR0107157A (en) | 2000-08-22 | 2002-07-16 | Brigham And Womens Hospital In | Diagnosis and treatment of cardiovascular conditions |
WO2002038794A2 (en) | 2000-11-09 | 2002-05-16 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
US6537221B2 (en) * | 2000-12-07 | 2003-03-25 | Koninklijke Philips Electronics, N.V. | Strain rate analysis in ultrasonic diagnostic images |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040253637A1 (en) | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
DE60235416D1 (en) | 2001-05-04 | 2010-04-01 | Biosite Inc | Diagnostic markers of acute coronary syndromes and their uses |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003022987A2 (en) | 2001-07-26 | 2003-03-20 | Eos Biotechnology, Inc. | Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection |
US6810284B1 (en) | 2001-11-21 | 2004-10-26 | Pacesetter, Inc. | Implantable cardiac stimulation system and method for monitoring diastolic function |
US7670769B2 (en) | 2002-05-09 | 2010-03-02 | The Brigham And Women's Hospital, Inc. | IL1RL-1 as a cardiovascular disease marker and therapeutic target |
WO2004056868A2 (en) | 2002-12-19 | 2004-07-08 | Endocube Sas | Nf-hev compositions and methods of use |
US20040133079A1 (en) | 2003-01-02 | 2004-07-08 | Mazar Scott Thomas | System and method for predicting patient health within a patient management system |
US20050123451A1 (en) | 2003-10-31 | 2005-06-09 | Hiroshi Nomura | System and apparatus for body fluid analysis using surface-textured optical materials |
CA3050151C (en) | 2003-11-26 | 2023-03-07 | Celera Corporation | Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof |
US20050196817A1 (en) | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP2005291899A (en) | 2004-03-31 | 2005-10-20 | Akira Matsumori | Examination method of heart disease |
EP1833766A1 (en) | 2004-12-17 | 2007-09-19 | Clearwater Systems Corp. | Method and apparatus for treating fluids |
EP1731910A1 (en) | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
JP5383480B2 (en) | 2006-04-24 | 2014-01-08 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | Predict fatality and detect serious disease |
ATE517341T1 (en) | 2006-04-27 | 2011-08-15 | Critical Care Diagnostics Inc | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PREDICTION OF CARDIOVASCULAR DISEASES |
EP3059594A1 (en) | 2006-05-01 | 2016-08-24 | Critical Care Diagnostics, Inc. | Prognosis of cardiovascular disease |
PL2019965T3 (en) | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics Inc | Differential diagnosis between pulmonary and cardiovascular disease |
US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
CA2705500A1 (en) | 2007-05-11 | 2008-11-20 | Tufts Medical Center | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
GB0713404D0 (en) | 2007-07-11 | 2007-08-22 | Integra Sp Ipr Ltd | Altio graph |
WO2009040133A1 (en) | 2007-09-26 | 2009-04-02 | Universitätsklinikum Heidelberg | Osteopontin as novel prognostic biomarker for heart failure |
FR2923029B1 (en) | 2007-10-26 | 2009-11-20 | Minima | GLASSES OF TYPE WITHOUT ENTOURAGE WITH WIRED BRANCHES |
PT2660599E (en) | 2008-04-18 | 2014-11-28 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
CN102812359A (en) | 2009-11-13 | 2012-12-05 | Bg医药公司 | Risk Factors And Prediction Of Myocardial Infarction |
WO2011127412A2 (en) | 2010-04-09 | 2011-10-13 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
JP6215713B2 (en) | 2011-03-17 | 2017-10-18 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | How to predict the risk of adverse clinical outcomes |
PL2734222T3 (en) | 2011-07-18 | 2017-03-31 | Critical Care Diagnostics, Inc. | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
ES2709697T3 (en) | 2012-05-18 | 2019-04-17 | Critical Care Diagnostics Inc | Procedures for treatment or prediction of the risk of a ventricular tachyarrhythmia event |
CN107478841A (en) | 2012-08-16 | 2017-12-15 | 重症监护诊断股份有限公司 | The method of risk of hypertension is suffered from prediction |
SG11201501271TA (en) | 2012-08-21 | 2015-03-30 | Critical Care Diagnostics Inc | Multimarker risk stratification |
JP6178687B2 (en) | 2013-09-27 | 2017-08-09 | 富士機械工業株式会社 | Gravure coating equipment |
CN106461636A (en) | 2014-01-10 | 2017-02-22 | 重症监护诊断股份有限公司 | Methods and systems for determining risk of heart failure |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2001
- 2001-11-08 WO PCT/US2001/046816 patent/WO2002038794A2/en not_active Application Discontinuation
- 2001-11-08 AU AU2002218026A patent/AU2002218026A1/en not_active Abandoned
- 2001-11-08 US US10/024,607 patent/US7432060B2/en not_active Expired - Lifetime
-
2008
- 2008-07-02 US US12/167,143 patent/US7985558B2/en not_active Expired - Fee Related
-
2011
- 2011-06-01 US US13/151,012 patent/US8530173B2/en not_active Expired - Lifetime
-
2013
- 2013-03-07 US US13/788,922 patent/US8871452B2/en not_active Expired - Lifetime
-
2014
- 2014-10-24 US US14/523,694 patent/US9857379B2/en not_active Expired - Lifetime
-
2017
- 2017-12-29 US US15/858,661 patent/US20180156818A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9857379B2 (en) | 2018-01-02 |
US7432060B2 (en) | 2008-10-07 |
US20130317030A1 (en) | 2013-11-28 |
WO2002038794A2 (en) | 2002-05-16 |
US7985558B2 (en) | 2011-07-26 |
US20050130136A1 (en) | 2005-06-16 |
US20110280887A1 (en) | 2011-11-17 |
US8871452B2 (en) | 2014-10-28 |
US20180156818A1 (en) | 2018-06-07 |
US20150177259A1 (en) | 2015-06-25 |
WO2002038794A3 (en) | 2003-09-12 |
US20090192078A1 (en) | 2009-07-30 |
US8530173B2 (en) | 2013-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002218026A1 (en) | Cardiovascular disease diagnostic and therapeutic targets | |
AU2001275177A1 (en) | Cardiac disease treatment and device | |
AU2001275176A1 (en) | Cardiac disease treatment and device | |
AU2001253565A1 (en) | Cardiac disease treatment and device | |
AU2001281369A1 (en) | Cardiac disease treatment and device | |
AU2002348226A1 (en) | Invasive therapeutic probe | |
AU5468301A (en) | Ablation and imaging catheter | |
AU2002952993A0 (en) | Therapeutic and diagnostic agents | |
AU715620C (en) | Therapeutic methods and uses | |
AU2002258728A1 (en) | Gene brcc-3 and diagnostic and therapeutic uses thereof | |
AU2002305151A1 (en) | Gene scc-112 and diagnostic and therapeutic uses thereof | |
AU2002303261A1 (en) | Gene brcc2 and diagnostic and therapeutic uses thereof | |
AU2001244602A1 (en) | Drugs retained in target tissue over long time | |
AU2001243515A1 (en) | Combination drug therapy | |
AU6092900A (en) | Animals comprising human hepatocellular tissue | |
AU2002248213A1 (en) | Markers for disease susceptibility and targets for therapy | |
AU2002210916A1 (en) | Endoscope attachment and endoscope | |
AU2002227925A1 (en) | Human beta-defensin-3 | |
AU2001286341A1 (en) | Therapeutic bio-energy unit | |
AU6835300A (en) | Diagnostic kit and use thereof | |
IL151019A0 (en) | Microcompetition and human disease | |
AU2001247841A1 (en) | Medical procedure | |
AU2001253024A1 (en) | Diagnosis and treatment of gastrointestinal disease | |
AUPQ048799A0 (en) | Diagnosis of cardiovascular disease | |
AU2001241778A1 (en) | Methods and compositions for the diagnosis and treatment of cardiovascular, hepatic, and bone disease |